<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Transl Androl Urol</journal-id><journal-id journal-id-type="iso-abbrev">Transl Androl Urol</journal-id><journal-id journal-id-type="publisher-id">TAU</journal-id><journal-title-group><journal-title>Translational Andrology and Urology</journal-title></journal-title-group><issn pub-type="epub">2223-4691</issn><publisher><publisher-name>AME Publishing Company</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4842547</article-id><article-id pub-id-type="publisher-id">tau-05-S1-AB069</article-id><article-id pub-id-type="doi">10.21037/tau.2016.s069</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>AB069. The effect of Seoritae extract in men with mild-to-moderate lower urinary tract symptoms suggestive of benign prostatic hyperplasia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bae</surname><given-names>Woong Jin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bashraheel</surname><given-names>Fahad</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Sae Woong</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Su Jin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yoon</surname><given-names>Byung Il</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Sae Woong</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff><target id="aff1" target-type="aff"><sup>1</sup></target>Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Republic of <country>Korea</country>; <target id="aff2" target-type="aff"><sup>2</sup></target>Department of Urology, The Catholic Kwandong University of Korea, International St Mary&#x02019;s hospital, Incheon, Republic of <country>Korea</country></aff></contrib-group><pub-date pub-type="epub-ppub"><month>4</month><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>4</month><year>2016</year></pub-date><volume>5</volume><issue>Suppl 1</issue><elocation-id>AB069</elocation-id><permissions><copyright-statement>2016 Translational Andrology and Urology. All rights reserved.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Translational Andrology and Urology.</copyright-holder></permissions><abstract><sec><title>Objective</title><p>We evaluated the effects of Seoritae extract (SE) on mild-to-moderate lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).</p></sec><sec><title>Methods</title><p>Seventy-six subjects with mild to moderate LUTS suggestive of BPH were prospectively recruited from the urology outpatient clinic, and assigned to either SE (4,200 mg or 6 tablets 3 times a day) or matching placebo. The primary outcome variable, the International Prostatic Symptom Score (IPSS), was evaluated at baseline and at 4 and 12 weeks. Post-void residual (PVR) volume, maximum urine flow rate (Qmax), and prostate-specific antigen (PSA) levels, were evaluated.</p></sec><sec><title>Results</title><p>IPSSs decreased significantly from baseline to 12 weeks within the SE group. Significant improvements in IPSS voiding scores at 4 and 12 weeks were also observed in the SE group compared to the placebo group. IPSS storage and quality of life scores were also significantly decreased at 12 weeks in the SE group. There was no change in Qmax or PVR in both groups after 12 weeks.</p></sec><sec><title>Conclusions</title><p>Administration of SE for 12 weeks led to significant improvements in LUTS, and it could be safely and effectively recommended for men with LUTS.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>Lower urinary tract symptoms (LUTS)</kwd><kwd>Seoritae extract (SE)</kwd><kwd>benign prostatic hyperplasia (BPH)</kwd></kwd-group></article-meta></front></article>